工程控制释放类固醇疗法:自组装微粒的制造和分子设计
Oluwaseun D Akanbi1, Michael L Felder1, Daniel Kupor1
1Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Science advances
|February 20, 2026
概括
基于颗粒的类固醇药物为肝脏疾病和炎症提供长时间的治疗效果. 这项研究开发了新的类固醇微粒,改善了药物输送,减少了频繁剂量的需要.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 计算化学计算化学
背景情况:
- 类固醇药物 (胆盐,皮质类固醇) 治疗肝功能障碍和炎症,但在体内半衰期短.
- 快速清除需要频繁的剂量,限制治疗疗效和患者的遵守.
- 基于粒子的药物输送系统对于持续的治疗活动至关重要.
研究的目的:
- 开发新的类固醇微粒,以提高药物输送效率.
- 研究制造方法和影响微粒子形成和形态的因素.
- 探索基于粒子的类固醇疗法的临床转化潜力.
主要方法:
- 通过金属或有机酸促进的三种不同的工艺制造的类固醇微粒.
- 粒子形状,大小和结晶性的表征.
- 粗粒度计算建模以阐明结在粒子形成中的作用.
- 化学修改类固醇C21侧组以调整粒子形态.
主要成果:
- 制造的类固醇微粒显示出一致的形状,大小和结晶性.
- 计算模型揭示了键是粒子形态学的关键决定因素.
- 通过C21侧组的化学修饰,成功调整了类固醇颗粒的形成和形态.
结论:
- 建立了制造具有可控性质的类固醇微粒的新方法.
- 对控制类固醇颗粒形成的分子相互作用的理解有所进步.
- 这项工作支持基于粒子的类固醇疗法的临床转化,作为传统配方的改进替代品.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
38
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
38
Modified-Release Drug Delivery Systems: Classification
47
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
47
Site-Targeted Drug Delivery Systems: Polymeric Carriers
36
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
36
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
38
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
38
Modified-Release Drug Delivery Systems: Site-Targeted
33
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
33
Intrauterine Drug Delivery Systems
34
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
34


